Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Breast Cancer On The Latest Cancer Waiting Times Stats, Released Today
Dr Alexis Willett, Head of Policy & Involvement at Breakthrough Breast Cancer, says:
generic viagra online
430,000 West Virginians Are In Families That Will Spend More Than 10 Percent Of Their Income On Health Care In 2009
A report released by the consumer health organization Families USA spotlights a growing crisis among insured families, as rising health care costs devour a growing portion of their pre-tax income.
News of the day
Ex-Child Soldiers: From Victims Of War To Protagonists Of Peace
Two young people, former child soldiers, who have transformed their brutal life experiences toward helping the more than one billion children whose lives are currently touched by war today told the international community, including Franco Frattini, the Italian Minister of Foreign Affairs, and Giovanni Alemanno, Mayor of Rome, what must be done to ensure that children are fully protected even in the heat of war.
Health Insurance

Biogen Idec Receives Fast Track Designation From FDA For PEGylated Interferon Beta-1a For Relapsing Multiple Sclerosis

Biogen Idec (NASDAQ: BIIB) announced the U.S. Food and Drug Administration (FDA) has granted PEGylated interferon beta-1a (BIIB017) Fast Track designation for relapsing multiple sclerosis (RMS). Biogen Idec is currently enrolling patients in a global Phase III study evaluating the efficacy and safety of either bi-weekly or once-monthly injections of PEGylated interferon beta-1a in this patient population. "Early-stage clinical trials suggest that PEGylated interferon beta-1a has the potential to offer less frequent dosing without compromising efficacy, which would be a significant development for people living with multiple sclerosis," said Michael Panzara, M.D., M.P.H., vice president and chief medical officer of neurology at Biogen Idec. "We look forward to working closely with the FDA to expedite the compound"s development and review process." The FDA"s Fast Track program is designed to expedite the review of new drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. Biogen Idec plans to enroll more than 1,200 patients in the Phase III, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of PEGylated interferon beta-1a in patients with RMS. The global trial, called ADVANCE, will determine the efficacy of PEGylated interferon beta-1a in reducing relapse rates in patients with RMS at one year. The study will also examine if, over time, treatment with PEGylated interferon beta-1a can slow disease progression and lead to a decrease in the number of T2 hyperintense brain lesions commonly seen in MS patients. Biogen Idec


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009